Dr Hung-Kai Kevin Chen, co-founder and CEO of Elixiron Immunotherapeutics, an innovative rising biotech focused on immunotherapeutic solutions, describes the company’s unique approach to developing new treatment methods for two disease areas with massive unmet medical need: hard-to-treat cancer and chronic hepatitis B. Dr Chen goes on to share his vision for using reverse-translation research and an immunology approach to position Elixiron into one of Taiwan’s rising stars in biotech.
“Begin with the end” is our strategy. Every project in Elixiron starts with an examination of a real-world problem in patients from which we then determine the disease-causing mechanisms and potential therapeutic approaches
